Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
PLoS One ; 8(2): e55449, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23457470

RESUMO

OBJECTIVE: Determine the acceptability and epidemiological impact of increases in HIV testing in gay men in New South Wales (NSW), Australia- particularly pertinent when considering treatment as prevention and the need to reduce undiagnosed infections. METHODS: We conducted an online survey and focus groups to assess whether increases in HIV testing would be acceptable to gay men in NSW. In parallel, we assessed the potential impact of increases in testing coverage and/or frequency using an individual-based model of HIV transmission. RESULTS: If sexual practices and the rate of initiating HIV treatment are unchanged then increasing HIV testing reduces infections. Increasing testing frequency has the largest impact, with a 13.8% reduction in HIV infections over 10 years if the ∼55-75% of men who test at least once per year increased their testing frequency to four times per year. If testing levels decrease from current levels then we expect an increase in HIV infections with a sharply rising trend over time. Increasing HIV testing would be acceptable if testing was more convenient. However, only ∼25% of men surveyed were 'very likely' to increase their level of HIV testing. Men delayed or avoided testing due to the slowness in obtaining results and if they believed they had not put themselves at risk. CONCLUSIONS: An increase in HIV testing alone is unlikely to reduce HIV incidence substantially in NSW gay men- however, the relatively high testing levels need to continue to prevent an increase in HIV infections. In jurisdictions with lower levels of HIV testing, increases in testing coverage and frequency are likely to have a larger impact. Successful treatment as prevention interventions will require increases in testing rates; such increases would be acceptable to gay men in NSW but only if more convenient testing and rapid communication of results were available.


Assuntos
Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , HIV/isolamento & purificação , Adulto , Coleta de Dados , Infecções por HIV/transmissão , Homossexualidade Masculina , Humanos , Incidência , Masculino , Modelos Biológicos , New South Wales/epidemiologia , Assunção de Riscos , Comportamento Sexual , Parceiros Sexuais
2.
Sex Health ; 9(2): 144-51, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22498158

RESUMO

OBJECTIVES: The number of incident infections of syphilis and HIV have increased over the past decade across Australia, particularly among gay men. In other industrialised settings, syphilis epidemics have also resurged coincidentally with increases in HIV diagnoses. Sexually transmissible infections (STI) are a biologically plausible cofactor for increasing HIV transmission. We pose the question: could strategies purely targeting syphilis also have an indirect impact on HIV incidence? METHODS: We developed an agent-based computer model that simulates the transmission and disease progression of HIV and syphilis among a population of sexually active gay men, calibrated to reflect the epidemics in Victoria, Australia. The model was informed by detailed behavioural data from a variety of sources and was used to investigate the potential epidemiological impact of different public health interventions. RESULTS: Assuming that syphilis could act as a biological cofactor for HIV transmission, from no effect to increasing risk by five-fold, our model indicates that if Australia's syphilis action plan is effectively implemented then the number of HIV infections could decrease by up to 48% over the next decade in the absence of any specific HIV interventions. CONCLUSION: It is plausible that effective implementation of interventions targeting syphilis epidemics can have an indirect effect of mitigating the spread of HIV. The possible effects of STI should be considered in the design, implementation and evaluation of public health strategies and programs.


Assuntos
Infecções por HIV/prevenção & controle , Implementação de Plano de Saúde/organização & administração , Homossexualidade Masculina/estatística & dados numéricos , Sífilis/prevenção & controle , Algoritmos , Causalidade , Comorbidade , Infecções por HIV/epidemiologia , Humanos , Masculino , Programas Nacionais de Saúde/organização & administração , Inovação Organizacional , Comportamento Sexual/estatística & dados numéricos , Sífilis/epidemiologia , Vitória
3.
Vaccine ; 29(36): 6086-91, 2011 Aug 18.
Artigo em Inglês | MEDLINE | ID: mdl-21723902

RESUMO

BACKGROUND: The RV144 trial conducted in Thailand was the first to demonstrate modest protective efficacy of an HIV vaccine. Its estimated initial efficacy was ∼74%, but this waned considerably over time. METHODS: We developed a mathematical model to reflect historical and current HIV trends across different at-risk populations in Thailand. The model was used to estimate the expected number of infections that would be averted if a vaccine with outcome characteristics similar to the RV144 vaccine was implemented in Thailand at varying levels of coverage. RESULTS: In the absence of a vaccine, we projected roughly 65,000 new HIV infections among adults during the period between 2011 and 2021. Due to the waning efficacy of the vaccine, vaccination campaigns were found to have modest long-term public health benefit unless re-vaccination occurred. We forecast that an RV144-like vaccine with coverage of 30% of the population would lead to a 3% reduction in HIV incidence during the next 10 years. In comparison, 30% coverage of annual or biennial re-vaccination with the vaccine was found to result in 23% and 14% reductions in incidence, respectively. Coverage of 60% without re-vaccination resulted in a 7% reduction. Epidemiological outcomes were found to depend primarily on three factors: vaccination coverage, vaccine efficacy, and the duration of protection the vaccine provided. DISCUSSION: Due to the short duration of protection the vaccine provides without re-vaccination, our model predicts modest benefit from a vaccination campaign with an RV144-like HIV vaccine in Thailand. Annual or biannual re-vaccination is predicted to greatly increase the long-term public health benefits of a vaccination campaign. The feasibility of vaccine implementation, as well as its economic viability, remains to be determined.


Assuntos
Vacinas contra a AIDS/administração & dosagem , Infecções por HIV/epidemiologia , Programas de Imunização/estatística & dados numéricos , Modelos Teóricos , Vacinas contra a AIDS/imunologia , Adolescente , Adulto , Ensaios Clínicos como Assunto , Feminino , HIV/imunologia , HIV/patogenicidade , Infecções por HIV/imunologia , Infecções por HIV/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Saúde Pública , Profissionais do Sexo , Tailândia/epidemiologia , Resultado do Tratamento , Vacinação , Adulto Jovem
4.
Vaccine ; 29(36): 6125-9, 2011 Aug 18.
Artigo em Inglês | MEDLINE | ID: mdl-21703320

RESUMO

A trial of the ALVAC-AIDSVAX HIV vaccine was recently found to be partially effective in preventing HIV transmission among study participants in Thailand. The success of this trial means that vaccination may become a viable intervention for the prevention of HIV infection in the medium-term future. Assuming that the vaccine has similar relative protective effectiveness per exposure event for reducing transmission among men who have sex with men (MSM) in high-income settings we investigated the potential population-level impact of rolling out such a vaccine among MSM in New South Wales, Australia. Using a detailed individual-based transmission model that simulates a population of sexually active MSM it was found that one-off intervention of 60% or 30% coverage of a vaccine with characteristics like the ALVAX-AIDSVAX vaccine would likely reduce the cumulative incidence of HIV by 9.6% and 5.1%, respectively, over a 10-year period. Due to the waning of vaccine efficacy, a booster vaccination could be required to maintain this reduction in incidence over the long term. If the previously vaccinated population is given a booster vaccine, with the same protection conferred as with the initial vaccination, every 5 years or every 2 years then the cumulative incidence over 10 years for 60% coverage could be reduced by 14.4% and 22.8%, respectively. Such a weak vaccine, with boosting, may be a potential intervention strategy for the prevention of HIV infection in MSM in high-income countries if further trials show boosting to be safe, acceptable, and cost-effective. However, the moderately low population-level impact suggests that a public health strategy involving such a vaccine should be supplemented with other biomedical and educational strategies.


Assuntos
Vacinas contra a AIDS/administração & dosagem , Infecções por HIV/epidemiologia , Programas de Imunização/estatística & dados numéricos , Modelos Teóricos , Vacinas contra a AIDS/imunologia , Circuncisão Masculina , HIV/imunologia , HIV/patogenicidade , Infecções por HIV/imunologia , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Humanos , Imunização Secundária , Incidência , Masculino , New South Wales/epidemiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Comportamento Sexual , Parceiros Sexuais , Vacinação
5.
Sex Transm Dis ; 38(7): 573-9, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21343845

RESUMO

BACKGROUND: Over the last decade, syphilis epidemics have resurged around the world, particularly among gay men. An innovative public health response could be the use of chemoprophylaxis. We sought out to determine the acceptability of syphilis chemoprophylaxis and its likely population effectiveness if it were adopted. METHODS: We conducted a mixed-methods study. An online survey (n = 2095 participants) and focus groups (n = 23 participants) were conducted to determine whether syphilis chemoprophylaxis is likely to be acceptable to gay men in Australia. We also developed an individual-based mathematical model that simulated a population of gay men, to explore the potential impact of introducing chemoprophylaxis. RESULTS: Of the 2095 gay men surveyed, 52.7% (95% confidence interval, 50.6%-54.8%) indicated that they would be very likely or slightly likely to use chemoprophylaxis to reduce their chance of acquiring syphilis, increasing to 75.8% (95% confidence interval, 74.0%-77.6%) if chemoprophylaxis would help reduce infections in the gay community. In this model, 70% use-effectiveness of chemoprophylaxis used by 50% of gay men is expected to reduce the number of syphilis cases by ∼50% after 12 months and 85% after 10 years. The majority of the prevention efforts can be gained by targeting subpopulations of men with higher sexual activity. CONCLUSIONS: Chemoprophylaxis offers promise as an acceptable and effective intervention for mitigating syphilis epidemics. The outcomes of a planned placebo-controlled syphilis chemoprophylaxis trial are eagerly anticipated.


Assuntos
Doxiciclina/uso terapêutico , Epidemias/prevenção & controle , Homossexualidade Masculina/estatística & dados numéricos , Aceitação pelo Paciente de Cuidados de Saúde , Sífilis/prevenção & controle , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Austrália/epidemiologia , Quimioprevenção , Epidemias/estatística & dados numéricos , Pesquisas sobre Atenção à Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Comportamento Sexual , Sífilis/epidemiologia , Sífilis/transmissão , Adulto Jovem
6.
PLoS One ; 5(6): e10981, 2010 Jun 08.
Artigo em Inglês | MEDLINE | ID: mdl-20544022

RESUMO

BACKGROUND: Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce. METHODS AND FINDINGS: We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains. CONCLUSIONS: If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies.


Assuntos
Fármacos Anti-HIV/farmacologia , Farmacorresistência Viral , Infecções por HIV/virologia , HIV/efeitos dos fármacos , Acessibilidade aos Serviços de Saúde , Fármacos Anti-HIV/uso terapêutico , Sudeste Asiático , Infecções por HIV/tratamento farmacológico , Humanos , Carga Viral
7.
Sex Transm Dis ; 37(5): 298-305, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20393383

RESUMO

BACKGROUND: The incidence of syphilis infections has been substantially increasing in gay men in the developed world. METHODS: We developed an individual-based mathematical model describing syphilis transmission within a gay male population: we used the model to simulate the expected relative impact of numerous screening and treatment interventions, targeting different at-risk groups with various coverage and frequency rates and follow-up schedules. RESULTS: The model predicts that increasing the proportion of gay men tested each year would have a relatively modest impact on syphilis incidence. However, increasing the frequency of testing can have a large impact, with the prevalence of syphilis reduced substantially if individuals are tested every 3 months. Targeting frequent screening at gay men who have large numbers of partners or who engage in group sex is a more efficient way of reducing syphilis epidemics. Contact tracing the regular partners of infected individuals is the most efficient intervention and can have a significant epidemiological impact with relatively high coverage rates. CONCLUSIONS: Increasing the frequency of testing and treatment are required to mitigate syphilis epidemics. Notifying and testing partners of infected men should occur where possible but the high rates required to reverse epidemic trends are likely to be infeasible. Contact tracing should be a secondary priority that is coupled with increases in the frequency of testing in the population. Encouraging testing among men not previously tested for syphilis is also recommended.


Assuntos
Transmissão de Doença Infecciosa/estatística & dados numéricos , Homossexualidade Masculina/estatística & dados numéricos , Parceiros Sexuais , Sífilis/prevenção & controle , Sexo sem Proteção/estatística & dados numéricos , Austrália , Busca de Comunicante , Surtos de Doenças/prevenção & controle , Humanos , Masculino , Programas de Rastreamento , Modelos Estatísticos , Vigilância da População , Sífilis/diagnóstico , Sífilis/epidemiologia , Sífilis/transmissão
8.
Curr HIV Res ; 7(6): 656-65, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19863480

RESUMO

OBJECTIVE: To evaluate the potential impact of the current global economic crisis (GEC) on the spread of HIV. DESIGN: To evaluate the impact of the economic downturn we studied two distinct HIV epidemics in Southeast Asia: the generalized epidemic in Cambodia where incidence is declining and the epidemic in Papua New Guinea (PNG) which is in an expansion phase. METHODS: Major HIV-related risk factors that may change due to the GEC were identified and a dynamic mathematical transmission model was developed and used to forecast HIV prevalence, diagnoses, and incidence in Cambodia and PNG over the next 3 years. RESULTS: In Cambodia, the total numbers of HIV diagnoses are not expected to be largely affected. However, an estimated increase of up to 10% in incident cases of HIV, due to potential changes in behavior, may not be observed by the surveillance system. In PNG, HIV incidence and diagnoses could be more affected by the GEC, resulting in respective increases of up to 17% and 11% over the next 3 years. Decreases in VCT and education programs are the factors that may be of greatest concern in both settings. A reduction in the rollout of antiretroviral therapy could increase the number of AIDS-related deaths (by up to 7.5% after 3 years). CONCLUSIONS: The GEC is likely to have a modest impact on HIV epidemics. However, there are plausible conditions under which the economic downturns can noticeably influence epidemic trends. This study highlights the high importance of maintaining funding for HIV programs.


Assuntos
Surtos de Doenças , Recessão Econômica , Infecções por HIV/epidemiologia , Antirretrovirais/uso terapêutico , Camboja/epidemiologia , Feminino , Previsões , HIV , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Necessidades e Demandas de Serviços de Saúde/economia , Humanos , Incidência , Masculino , Papua Nova Guiné/epidemiologia , Vigilância da População , Prevalência , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA